Strategic Partnerships Leverage ANT’s exclusive license from Cleveland Clinic and FDA Breakthrough Designation to position as a premier collaboration partner for interventional cardiology and peripheral vascular disease programs, targeting hospitals and medtech incubators seeking breakthrough DCB solutions.

Clinical Milestones Highlight progress toward U.S. pivotal trials for SirPlux Duo across coronary and peripheral indications to engage clinical study sites, contract research organizations, and payer networks interested in first-in-class dual-drug delivery technologies.

Funding Momentum Capitalize on recent Series B funding and multi-year fundraising trajectory to support business development efforts with potential strategic investors, joint ventures, and grant opportunities that accelerate commercialization and scale.

Targeted Markets Focus outreach on interventional centers tackling in-stent restenosis, small-vessel disease, and below-the-knee peripheral artery disease where dual-drug delivery with sustained tissue retention could differentiate outcomes and reduce reinterventions.

Accelerator Footprint Utilize ANT’s position as a portfolio company of T45 Labs and engagement with medtech incubators to identify pilot projects, co-development opportunities, and early-access programs with device manufacturers and hospital systems seeking innovative catheter-based therapies.